PRISM refracts new funds to fibrosis trial
This article was originally published in Scrip
Executive Summary
The Japanese venture PRISM Pharma has secured $15 million in new funding that it will use to take its lead development project, the Wnt/beta-catenin signaling modulator PRI-724, into the clinic for fibrosis.